In This Section

Program

Thursday, September 17, 2020

Friday, September 18, 2020

Thursday, September 17, 2020

Welcome and Opening Keynote Session
Moderator: Alex K. Shalek, Massachusetts Institute of Technology, Cambridge, Massachusetts
9:30 a.m.-10:05 a.m.

Welcome and Opening Remarks
Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, England

Introduction of Keynote
Alex K. Shalek, Massachusetts Institute of Technology, Cambridge, Massachusetts

Keynote Address
Single-cell analysis of CRISPR T cells
Carl H. June, University of Pennsylvania, Philadelphia, Pennsylvania

Break
10:05-10:20 a.m.
Plenary Session 1: Spatial Pathology – Technological Innovations
Moderator: R. Michael Angelo, Stanford University, Palo Alto, California
10:20-11:50 a.m.

Slide-seq: A platform for understanding cellular circuits in tissue
Fei Chen, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

Highly multiplexed imaging of tissues with subcellular resolution by imaging mass cytometry
Bernd Bodenmiller, University of Zurich, Zurich, Switzerland

Relating single-cell function to tissue structure in human tumors using MIBI-TOF
R. Michael Angelo, Stanford University, Palo Alto, California

Analysis of spatiotemporal phenotypic heterogeneity in chemoresistant triple-negative breast cancer using imaging mass cytometry*
Amanda Rinkenbaugh, The University of Texas MD Anderson Cancer Center, Houston, Texas

Break
11:50 a.m.-12:05 p.m.
Plenary Session 2: Spatial Pathology – Computational Developments
Moderator: Sylvia K. Plevritis, Stanford University, Stanford, California
12:05-1:10 p.m.

Deciphering the co-evolution of cancer and the microenvironment
Yinyin Yuan, Institute of Cancer Research, London, United Kingdom

Computational modeling of the tumor microenvironment
Sylvia K. Plevritis, Stanford University, Stanford, California

Inferring the evolutionary dynamics of ductal carcinoma in situ through multi-regional sequencing and mathematical modeling*
Marc D. Ryser, Duke University, Durham, North Carolina

Break
1:10-1:25 p.m.
Plenary Session 3: Defining and Targeting the Tumor Microenvironment
Moderator: Yardena Samuels, Weizmann Institute of Science, Rehovot, Israel
1:25-2:55 p.m.

UVB-induced tumor heterogeneity directs immune response in melanoma
Yardena Samuels, Weizmann Institute of Science, Rehovot, Israel

Tracking the impact of tumor mutations in the T cell differentiation landscape of lung cancer
Sergio Quezada, University College London Cancer Institute, London, United Kingdom

Genetic mechanisms underlying immunotherapy efficacy
Timothy A. Chan, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Subtype-specific microenvironmental crosstalk and tumor cell plasticity in metastatic pancreatic cancer*
Peter Winter, Massachusetts Institute of Technology, Cambridge, Massachusetts

Break
2:55-3:10 p.m.
Plenary Session 4: Clinical Insights for Targeting and Monitoring Cellular Heterogeneity
Moderator: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
3:10-4:40 p.m.

Uncovering the ecology of glioblastoma with spatial digital profiling and single cell genotyping
Michalina Janiszewska, The Scripps Research Institute Florida, Jupiter, Florida

Detecting and targeting cellular heterogeneity of the lymphoid blood malignancies
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts

Single cell multi-omics to define normal and malignant differentiation topologies
Dan-Avi Landau, Weill Cornell Medical College, New York, New York

Understanding tumor clonal evolution by single-cell transcriptomic analysis in liver cancer*
Lichun Ma, National Cancer Institute, Bethesda, Maryland

Friday, September 18, 2020

Plenary Session 5: Prevention and Premalignancies
Moderator: Nicholas E. Navin, UT MD Anderson Cancer Center, Houston, Texas
9:30 a.m.-11:00 a.m.

In the light of evolution: Why do we get more cancers in old age?
James V. DeGregori, University of Colorado Anschutz Medical Campus, Aurora, Colorado

Breast cancer evolution: Insights from single-cell genomics
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas

Inflammatory memory and tumorigenesis
Shruti Naik, New York University Langone Medical Center, New York, New York

Mapping the tumor and microenvironmental evolution underlying DCIS progression through multiplexed ion beam imaging*
Tyler Risom, Stanford University, Palo Alto, California

Break
11:00-11:15 a.m.
Plenary Session 6: Tumor Progression and Therapeutic Resistance
Moderator: Charles Swanton, The Francis Crick Institute, London, United Kingdom
11:15 a.m.-12:45 p.m.

Cancer evolution, immune evasion, and metastasis
Charles Swanton, The Francis Crick Institute, London, United Kingdom

Measuring and modeling cancer evolution with single-cell approaches
Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, New York

Genomic evolution of brain metastases: Implications for precision medicine
Priscilla K. Brastianos, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts

Stabilising selection causes grossly altered but stable karyotypes in metastatic colorectal cancer*
Salpie Nowinski, Barts Cancer Institute, Queen Mary University London, London, United Kingdom

Break
12:45-1 p.m.
Plenary Session 7: Liquid Tumors and Hematologic Malignancies
Moderator: Alex K. Shalek, Massachusetts Institute of Technology, Cambridge, Massachusetts
1-2:40 p.m.

Clonal heterogeneity and evolution of acute myeloid leukemia
Koichi Takahashi, The University of Texas MD Anderson Cancer Center, Houston, Texas

Aberrant leukemic developmental hierarchies and MRD-specific targeting informed by single-cell biophysical and molecular profiling
Alex K. Shalek, Massachusetts Institute of Technology, Cambridge, Massachusetts

Stem cells play a role in human leukemia from origin to relapse
John E. Dick, University of Toronto, Toronto, Ontario, Canada

Single cell proteomics to capture human dysplasia and dysfunction
Sean Bendall, Stanford University School of Medicine, Palo Alto, California

Break
2:40-2:55 p.m.
Plenary Session 8: Computational Advances in Tumor Analysis
Moderator: Peter Vasili Kharchenko, Harvard Medical School, Boston, Massachusetts
2:55-4:25 p.m.

Impact of metastatic prostate cancer on human bone marrow
Peter Vasili Kharchenko, Harvard Medical School, Boston, Massachusetts

Dissecting glioblastoma by single-cell RNA-seq
Itay Tirosh, Weizmann Institute of Science, Rehovot, Israel

Spatial characterization of the tumor-immune microenvironment through neoadjuvant HER2-targeted therapy
Christina Curtis, Stanford University, Stanford, California

A systems biology approach to reprogramming drug-resistant breast cancer stem-like cells*
Jeremy Worley, Columbia University, New York, New York

Break
4:25-4:40 p.m.
Keynote Address and Closing Remarks
Moderator: Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas
4:40-5:20 p.m.

Introduction of Keynote Speaker
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas

Keynote Address
Tumor evolution: From Darwin’s finches to breast cancer
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts

Closing Remarks

Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts